Regeneron Axokine Phase III Study Targets Broad Obesity Indication
Executive Summary
Regeneron's Phase III trial for the obesity treatment Axokine is enrolling 2,000 patients ranging from moderately to morbidly obese, CEO Leonard Schleifer, MD/PhD, told an Aug. 1 investor teleconference.